AAAAAA

   
Results: 1-16 |
Results: 16
THE ROLE OF INITIAL TRANSPLANTATION IN THE TREATMENT OF HIGH-RISK NHL
Authors: SCHENKEIN DP
Citation: Dp. Schenkein, THE ROLE OF INITIAL TRANSPLANTATION IN THE TREATMENT OF HIGH-RISK NHL, Leukemia & lymphoma (Print), 30, 1998, pp. 22-23
NEOPLASMS AND TRANSPLANTATION - TRADING SWORDS FOR PLOWSHARES
Authors: SCHENKEIN DP SCHWARTZ RS
Citation: Dp. Schenkein et Rs. Schwartz, NEOPLASMS AND TRANSPLANTATION - TRADING SWORDS FOR PLOWSHARES, The New England journal of medicine, 336(13), 1997, pp. 949-950
COMPARISON OF STANDARD AND SHORT-COURSE METHOTREXATE (MTX) IN COMBINATION WITH ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A (CSA) TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
Authors: KOC Y MILLER KB SCHENKEIN DP SPRAGUE K BERKMAN E
Citation: Y. Koc et al., COMPARISON OF STANDARD AND SHORT-COURSE METHOTREXATE (MTX) IN COMBINATION WITH ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A (CSA) TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD), Blood, 90(10), 1997, pp. 4413-4413
A PHASE-II TRIAL OF HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION - THE IMPACT OF INVOLVED FIELD RADIATION-THERAPY
Authors: BOYLE T MORR J ROITMAN D WAZER DE LAZARUS HM SCHENKEIN DP
Citation: T. Boyle et al., A PHASE-II TRIAL OF HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION - THE IMPACT OF INVOLVED FIELD RADIATION-THERAPY, Blood, 90(10), 1997, pp. 4547-4547
EVIDENCE FOR EARLY B-CELL ACTIVATION PRECEDING THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-NEGATIVE ACQUIRED IMMUNODEFICIENCY SYNDROME-RELATED LYMPHOMA
Authors: PRZYBYLSKI GK GOLDMAN J NG VL MCGRATH MS HERNDIER BG SCHENKEIN DP MONROE JG SILBERSTEIN LE
Citation: Gk. Przybylski et al., EVIDENCE FOR EARLY B-CELL ACTIVATION PRECEDING THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-NEGATIVE ACQUIRED IMMUNODEFICIENCY SYNDROME-RELATED LYMPHOMA, Blood, 88(12), 1996, pp. 4620-4629
A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION ASINITIAL THERAPY FOR HIGH-RISK NON-HODGKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY
Authors: SCHENKEIN DP ROITMAN D MILLER KB MORELLI J STADTMAUER E PECORA AL CASSILETH P LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION ASINITIAL THERAPY FOR HIGH-RISK NON-HODGKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 88(10), 1996, pp. 462-462
THE TREATMENT OF REFRACTORY OR SECONDARY LEUKEMIA WITH INDUCTION THERAPY AND AN ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO-BMT)
Authors: SPRAGUE KA MILLER KB SCHENKEIN DP HURLEY CA BERKMAN E
Citation: Ka. Sprague et al., THE TREATMENT OF REFRACTORY OR SECONDARY LEUKEMIA WITH INDUCTION THERAPY AND AN ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO-BMT), Blood, 88(10), 1996, pp. 2445-2445
IMPROVED SURVIVAL FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
Authors: MITUS AJ MILLER KB SCHENKEIN DP RYAN HF PARSONS SK WHEELER C ANTIN JH
Citation: Aj. Mitus et al., IMPROVED SURVIVAL FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 13(3), 1995, pp. 560-569
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
Authors: FRENETTE PS DESFORGES JF SCHENKEIN DP RABSON A SLAPACK CA MILLER KB
Citation: Ps. Frenette et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA, American journal of hematology, 49(1), 1995, pp. 48-55
LARGE-VOLUME LEUKAPHERESIS FOR COLLECTION OF MONONUCLEAR-CELLS FOR HEMATOPOIETIC RESCUE IN HODGKINS-DISEASE
Authors: COMENZO RL MALACHOWSKI ME MILLER KB ERBAN JK SCHENKEIN DP DESFORGES JF BERKMAN EM
Citation: Rl. Comenzo et al., LARGE-VOLUME LEUKAPHERESIS FOR COLLECTION OF MONONUCLEAR-CELLS FOR HEMATOPOIETIC RESCUE IN HODGKINS-DISEASE, Transfusion, 35(1), 1995, pp. 42-45
A 65-YEAR-OLD MAN WITH MEDIASTINAL HODGKINS-DISEASE AND A PELVIC MASS- SPLENOSIS
Authors: SCHENKEIN DP MURPHY BL HARRIS NL FINGOLD DR AHMED E
Citation: Dp. Schenkein et al., A 65-YEAR-OLD MAN WITH MEDIASTINAL HODGKINS-DISEASE AND A PELVIC MASS- SPLENOSIS, The New England journal of medicine, 333(12), 1995, pp. 784-791
A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL BOOD STEM-CELL (PBSC) TRANSPLANTATION AS INITIAL THERAPY FOR HIGH-RISK NON-HODSKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY
Authors: SCHENKEIN DP MILLER KB SWEET M ROSENBACH M STADTMAUER E CASSILETH P COOPER B LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL BOOD STEM-CELL (PBSC) TRANSPLANTATION AS INITIAL THERAPY FOR HIGH-RISK NON-HODSKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 86(10), 1995, pp. 3844-3844
ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A TO PREVENT GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: MILLER KB SCHENKEIN DP ERBAN JK COMENZO R FOGAREN T BERKMAN E RABSON A HIRSCH CA
Citation: Kb. Miller et al., ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A TO PREVENT GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Annals of hematology, 68(1), 1994, pp. 15-20
PHASE I II STUDY OF CYCLOPHOSPHAMIDE, CARBOPLATIN, AND ETOPOSIDE AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION WITH POSTTRANSPLANTINTERFERON ALFA-2B FOR PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE/
Authors: SCHENKEIN DP DIXON P DESFORGES JF BERKMAN E ERBAN JK ASCENSAO JL MILLER KB
Citation: Dp. Schenkein et al., PHASE I II STUDY OF CYCLOPHOSPHAMIDE, CARBOPLATIN, AND ETOPOSIDE AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION WITH POSTTRANSPLANTINTERFERON ALFA-2B FOR PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE/, Journal of clinical oncology, 12(11), 1994, pp. 2423-2431
A RANDOMIZED TRIAL OF FILGRASTIM (G-CSF) PRIMED PERIPHERAL-BLOOD STEM-CELLS (PBSC) VS BONE-MARROW AS A RECONSTITUTION SOURCE FOR HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE - AN INTERIM CLINICAL AND MOLECULAR ANALYSIS
Authors: SCHENKEIN DP MCCANN L KANTETI R BERKMAN E ERBAN J WECKSTEIN D SWEET M MILLER K
Citation: Dp. Schenkein et al., A RANDOMIZED TRIAL OF FILGRASTIM (G-CSF) PRIMED PERIPHERAL-BLOOD STEM-CELLS (PBSC) VS BONE-MARROW AS A RECONSTITUTION SOURCE FOR HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE - AN INTERIM CLINICAL AND MOLECULAR ANALYSIS, Blood, 84(10), 1994, pp. 10000204-10000204
RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG)
Authors: ROWE JM CIOBANU N ASCENSAO J STADTMAUER EA WEINER RS SCHENKEIN DP MCGLAVE P LAZARUS HM
Citation: Jm. Rowe et al., RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG), Annals of internal medicine, 120(2), 1994, pp. 143-158
Risultati: 1-16 |